Van Eck Associates Corp Red Hill Biopharma Ltd. Transaction History

Van Eck Associates Corp

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$5.98 - $7.51 $48,455 - $60,853	-8,103 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$6.98 - $11.29 $830 - $1,343	119 Added 1.49%	8,103 $59,000
Q4 2020 Feb 09, 2021	SELL	$7.81 - $10.39 $1,601 - $2,129	-205 Reduced 2.5%	7,984 $65,000
Q3 2020 Nov 12, 2020	BUY	$6.34 - $10.83 $1,077 - $1,841	170 Added 2.12%	8,189 $84,000
Q2 2020 Aug 10, 2020	SELL	$4.6 - $8.6 $13,914 - $26,015	-3,025 Reduced 27.39%	8,019 $54,000
Q1 2020 May 12, 2020	BUY	$3.51 - $6.17 $1,323 - $2,326	377 Added 3.53%	11,044 $50,000
Q4 2019 Feb 13, 2020	BUY	$5.76 - $7.35 $6,981 - $8,908	1,212 Added 12.82%	10,667 $65,000
Q3 2019 Nov 08, 2019	BUY	$6.46 - $8.37 $206 - $267	32 Added 0.34%	9,455 $67,000
Q2 2019 Aug 07, 2019	SELL	$6.34 - $8.8 $10,277 - $14,264	-1,621 Reduced 14.68%	9,423 $61,000
Q1 2019 May 13, 2019	BUY	$6.06 - $9.0 $1,557 - $2,313	257 Added 2.38%	11,044 $92,000
Q4 2018 Feb 12, 2019	BUY	$5.18 - $9.35 $16,550 - $29,873	3,195 Added 42.08%	10,787 $60,000
Q3 2018 Nov 13, 2018	BUY	$6.0 - $11.35 $2,610 - $4,937	435 Added 6.08%	7,592 $67,000
Q2 2018 Aug 13, 2018	BUY	$4.82 - $8.53 $14,315 - $25,334	2,970 Added 70.93%	7,157 $61,000
Q1 2018 May 11, 2018	BUY	$4.96 - $6.84 $1,388 - $1,915	280 Added 7.17%	4,187 $22,000
Q4 2017 Feb 12, 2018	SELL	$4.58 - $10.81 $7,364 - $17,382	-1,608 Reduced 29.16%	3,907 $20,000
Q3 2017 Nov 09, 2017	BUY	$8.25 - $10.81 $2,029 - $2,659	246 Added 4.67%	5,515 $60,000
Q2 2017 Aug 11, 2017	BUY	N/A	5,269	5,269 $45,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

Stay updated on Van Eck Associates Corp with notifications on news.